Want to see IN:DRREDDY full AI Analyst Report?
Dr. Reddy's Laboratories Ltd. (DRREDDY) Ratios
Dr. Reddy's Laboratories Ltd. Ratios
IN:DRREDDY's free cash flow for Q2 2027 was $2.27B. For the 2027 fiscal year, IN:DRREDDY's free cash flow was decreased by $-2.40B and operating cash flow was $4.67B. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.80 | 1.92 | 2.58 | 2.38 | 1.93 |
| Quick Ratio | 1.35 | 1.37 | 1.92 | 1.82 | 1.39 |
| Cash Ratio | 0.09 | 0.11 | 0.07 | 0.07 | 0.16 |
| Solvency Ratio | 0.32 | 0.46 | 0.65 | 0.64 | 0.33 |
| Operating Cash Flow Ratio | 0.32 | 0.36 | 0.47 | 0.69 | 0.30 |
| Short-Term Operating Cash Flow Coverage | 0.86 | 1.22 | 3.57 | 5.26 | 1.04 |
| Net Current Asset Value | $ 103.09B | $ 94.29B | $ 141.08B | $ 114.27B | $ 74.98B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.09 | 0.05 | 0.04 | 0.11 |
| Debt-to-Equity Ratio | 0.24 | 0.14 | 0.07 | 0.06 | 0.18 |
| Debt-to-Capital Ratio | 0.19 | 0.12 | 0.07 | 0.06 | 0.15 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.02 | 0.01 | 0.00 | 0.02 |
| Financial Leverage Ratio | 1.54 | 1.48 | 1.38 | 1.40 | 1.56 |
| Debt Service Coverage Ratio | 1.00 | 1.70 | 4.37 | 4.02 | 1.39 |
| Interest Coverage Ratio | 12.42 | 25.40 | 39.58 | 40.02 | 30.77 |
| Debt to Market Cap | 0.07 | 0.05 | 0.02 | 0.01 | 0.04 |
| Interest Debt Per Share | 112.07 | 59.45 | 26.07 | 17.91 | 41.85 |
| Net Debt to EBITDA | 0.94 | 0.36 | 0.16 | 0.12 | 0.40 |
| Profitability Margins | |||||
| Gross Profit Margin | 52.77% | 58.50% | 58.61% | 56.67% | 53.10% |
| EBIT Margin | 17.43% | 22.43% | 23.49% | 21.72% | 16.75% |
| EBITDA Margin | 23.56% | 27.29% | 28.40% | 26.86% | 22.27% |
| Operating Profit Margin | 13.83% | 22.07% | 24.26% | 23.24% | 13.75% |
| Pretax Profit Margin | 16.32% | 23.59% | 25.74% | 24.55% | 15.06% |
| Net Profit Margin | 12.76% | 17.37% | 19.95% | 18.33% | 10.99% |
| Continuous Operations Profit Margin | 12.64% | 17.58% | 19.95% | 18.33% | 10.99% |
| Net Income Per EBT | 78.17% | 73.64% | 77.48% | 74.66% | 72.97% |
| EBT Per EBIT | 118.03% | 106.88% | 106.11% | 105.64% | 109.57% |
| Return on Assets (ROA) | 7.40% | 11.47% | 14.37% | 13.96% | 7.94% |
| Return on Equity (ROE) | 11.36% | 16.96% | 19.85% | 19.51% | 12.37% |
| Return on Capital Employed (ROCE) | 11.28% | 19.81% | 23.24% | 24.10% | 14.55% |
| Return on Invested Capital (ROIC) | 7.54% | 13.34% | 17.18% | 17.11% | 9.32% |
| Return on Tangible Assets | 9.29% | 14.71% | 16.08% | 15.72% | 8.89% |
| Earnings Yield | 4.10% | 5.88% | 5.34% | 5.86% | 3.30% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.73 | 3.60 | 3.48 | 2.86 | 2.67 |
| Payables Turnover | 4.75 | 6.74 | 5.36 | 5.97 | 6.30 |
| Inventory Turnover | 2.07 | 1.90 | 1.82 | 2.19 | 1.98 |
| Fixed Asset Turnover | 2.90 | 3.33 | 3.63 | 4.35 | 3.45 |
| Asset Turnover | 0.58 | 0.66 | 0.72 | 0.76 | 0.72 |
| Working Capital Turnover Ratio | 2.64 | 2.40 | 2.06 | 2.39 | 2.82 |
| Cash Conversion Cycle | 233.02 | 239.25 | 237.67 | 233.07 | 263.39 |
| Days of Sales Outstanding | 133.83 | 101.38 | 104.99 | 127.50 | 136.66 |
| Days of Inventory Outstanding | 176.05 | 192.04 | 200.74 | 166.75 | 184.71 |
| Days of Payables Outstanding | 76.86 | 54.17 | 68.06 | 61.18 | 57.97 |
| Operating Cycle | 309.88 | 293.42 | 305.72 | 294.25 | 321.37 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 64.68 | 55.66 | 54.50 | 70.76 | 33.80 |
| Free Cash Flow Per Share | 36.65 | 22.69 | 21.59 | 48.09 | 10.89 |
| Dividend Paid and CapEx Coverage Ratio | 1.80 | 1.36 | 1.33 | 2.47 | 1.21 |
| Capital Expenditure Coverage Ratio | 2.31 | 1.69 | 1.66 | 3.12 | 1.48 |
| Operating Cash Flow Coverage Ratio | 0.60 | 0.99 | 2.27 | 4.37 | 0.83 |
| Operating Cash Flow to Sales Ratio | 0.16 | 0.14 | 0.16 | 0.24 | 0.13 |
| Free Cash Flow Yield | 2.92% | 1.97% | 1.73% | 5.20% | 1.27% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 24.38 | 17.00 | 18.71 | 17.07 | 30.32 |
| Price-to-Sales (P/S) Ratio | 3.11 | 2.95 | 3.73 | 3.13 | 3.33 |
| Price-to-Book (P/B) Ratio | 2.77 | 2.88 | 3.71 | 3.33 | 3.75 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 34.24 | 50.79 | 57.90 | 19.23 | 78.87 |
| Price-to-Operating Cash Flow Ratio | 19.40 | 20.70 | 22.94 | 13.07 | 25.42 |
| Price-to-Earnings Growth (PEG) Ratio | -1.01 | 11.59 | 0.80 | 0.19 | 0.83 |
| Enterprise Value Multiple | 14.13 | 11.18 | 13.31 | 11.76 | 15.36 |
| Enterprise Value | 1.12T | 993.25B | 1.05T | 776.88B | 733.48B |
| EV to EBITDA | 14.13 | 11.18 | 13.31 | 11.76 | 15.36 |
| EV to Sales | 3.33 | 3.05 | 3.78 | 3.16 | 3.42 |
| EV to Free Cash Flow | 36.67 | 52.49 | 58.62 | 19.42 | 80.97 |
| EV to Operating Cash Flow | 20.78 | 21.39 | 23.22 | 13.20 | 26.09 |
| Tangible Book Value Per Share | 315.37 | 273.99 | 287.13 | 236.39 | 191.02 |
| Shareholders’ Equity Per Share | 453.00 | 399.66 | 336.56 | 277.65 | 229.09 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.23 | 0.25 | 0.23 | 0.25 | 0.27 |
| Revenue Per Share | 403.59 | 390.25 | 334.89 | 295.54 | 257.78 |
| Net Income Per Share | 51.48 | 67.78 | 66.80 | 54.17 | 28.34 |
| Tax Burden | 0.78 | 0.74 | 0.77 | 0.75 | 0.73 |
| Interest Burden | 0.94 | 1.05 | 1.10 | 1.13 | 0.90 |
| Research & Development to Revenue | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 |
| SG&A to Revenue | 0.32 | 0.29 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.27 | 0.82 | 0.82 | 0.97 | 1.19 |
Currency in INR